In terms of potential therapeutic targets, based on this study, all potential biotargets of TJQW action against COVID-19 were methodically obtained, and the potential core pharmacological targets were identified as EGFR, CASP3, STAT3, ESR1, FPR2, F2, BCL2L1, BDKRB2, MPO, and ACE, majority of them have been confirmed to be involved in pulmonary inflammation. This evidence concerns the gene BDKRB2 and COVID-19.